FDA Proposes Not to Include Popular Drugs Like Semaglutide on Compounding List

You might care about this because the Food and Drug Administration (FDA) is looking at a list of bulk drug substances that can be used by certain drug compounding facilities. These facilities, called outsourcing facilities, can prepare medications in bulk without individual patient prescriptions, often for use in doctors' offices. The FDA needs to create a special list, known as the 503B Bulks List, for these substances if there's a clinical need for them to be compounded. This document announces that the FDA has reviewed three specific substances that were nominated for this list: semaglutide, tirzepatide, and liraglutide. All three of these are active ingredients in popular prescription medications, often used for diabetes or weight management. The FDA is proposing not to add these three substances to the 503B Bulks List. This means that outsourcing facilities might not be allowed to compound drugs using these bulk ingredients. The FDA is asking for public comments on this proposal until June 30, 2026. Their decision is based on whether there is a clear "clinical need" for these specific bulk substances to be available for compounding by these facilities, taking into account patient safety and existing approved drug products. If they are not added, facilities would generally need specific patient prescriptions or a drug shortage to compound them. What makes this notice interesting is that it deals with commonly discussed and used medications. Semaglutide, tirzepatide, and liraglutide have gained significant attention for their effectiveness in treating conditions like type 2 diabetes and obesity. The FDA's proposal highlights the strict rules around how certain drugs can be compounded, especially when they are already available as FDA-approved, manufactured products. The process outlined in Section 503B of the Federal Food, Drug, and Cosmetic Act is designed to balance patient access to custom-made medications with the need for safety and quality control. By proposing to exclude these substances, the FDA is essentially stating that, at this time, they do not see a specific clinical need for outsourcing facilities to compound these drugs from bulk ingredients. This is important because it impacts how these drugs might be prepared and distributed, and it emphasizes the FDA's role in regulating the drug supply to protect public health. The decision-making process involves careful review and public input, ensuring transparency in these important regulatory choices. Several groups will find this legal document highly relevant. First, outsourcing facilities and other pharmacies that engage in drug compounding will be directly affected by this decision, as it dictates which bulk substances they can use. Healthcare providers, including endocrinologists, primary care physicians, and weight management specialists who prescribe or administer medications containing semaglutide, tirzepatide, or liraglutide, will want to understand the implications for their patients. Patients currently using or considering compounded versions of these drugs for diabetes or weight management should also pay attention, as it could influence their treatment options. Manufacturers of the brand-name versions of these drugs, such as Ozempic, Wegovy, Mounjaro, and Zepbound, will also be interested, as this proposal could affect the market for their products. Finally, legal professionals specializing in pharmaceutical law, regulatory affairs, and health policy will find this document useful for understanding FDA's interpretation and application of Section 503B.